Restoring the Balance
Venturing into the unknown to harness the microbiome for human health
Maryam Mahdi | | Interview
Young biotech company Rebiotix is using microbiome science to treat gastrointestinal (GI) disease and is involved in a number of clinical trials. Specifically, Rebiotix’ Microbiota Restoration Therapy drug platform aims to deliver human-derived microbes into a sick patient’s intestinal tract. Here, Lee Jones, founder, president and CEO at Rebiotix, explains how the changing landscape of microbiome R&D is shaping conversations with regulators and helping create metrics for patient norms.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.